Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04440631
Other study ID # Microbiome
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2019
Est. completion date December 31, 2022

Study information

Verified date February 2023
Source AO Research Institute Davos
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The microbiome of 80 orthopedic-device related infection (ODRI) patients treated with antibiotics and 10 healthy controls will be investigated. Samples (blood, stool, saliva, skin-swab) are collected 4x within 6 months. Composition and diversity of the microbiome will be assessed by 16sRNA sequencing, skins swabs are screened for rifampicin-resistant staphylococci onto Mannitol-salt-agar plates supplemented with rifampicin, inflammation markers and antibodies in blood and saliva are monitored to track changes in the immune response. For further analysis patients are assigned to one of two groups: 1) antibiotic therapy including rifampicin and 2) non-rifampicin antibiotic therapy.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date December 31, 2022
Est. primary completion date June 1, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The patient is planned to undergo revision surgery due to suspected bone or joint infection. - The patient is at least 18 years old Exclusion Criteria: - The patient took antibiotics in the previous six weeks of recruitment (a single dose/"shot" of antibiotics during this period is not considered). - The patient suffers from gut-associated morbidities such as Morbus Crohn or colitis ulcerosa. - The patient suffers from psychiatric disorders/cognitive impairment affecting understanding. - The patient is unable to give consent and follow procedures and/or has insufficient knowledge of the project language.

Study Design


Intervention

Other:
no intervention, observational only
no intervention, observational only

Locations

Country Name City State
Switzerland Universitätsspital Basel Basel
Switzerland Schulthess Klinik Zürich Zürich

Sponsors (1)

Lead Sponsor Collaborator
AO Research Institute Davos

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Level of systemic Inflammation following two weeks of iv antibiotic therapy Inflammatory cytokines in the blood will be measured and compared to baseline samples of the patients. Two weeks
Other Level of systemic Inflammation following four weeks of oral antibiotic therapy Inflammatory cytokines in the blood will be measured and compared to baseline samples of the patients. Six weeks (including two weeks iv and four weeks of oral antibiotic therapy)
Other Level of systemic Inflammation 24 weeks after antibiotic therapy start Inflammatory cytokines in the blood will be measured and compared to baseline samples of the patients. 24 weeks
Other Monitoring mucosal immune response following two weeks of iv antibiotic therapy IgA levels will measured in saliva of the patients and compared to baseline samples of the patients. Two weeks
Other Monitoring mucosal immune response following four weeks of oral antibiotic therapy IgA levels will measured in saliva of the patients and compared to baseline samples of the patients. Six weeks (including two weeks iv and four weeks of oral antibiotic therapy)
Other Monitoring mucosal immune response 24 weeks after antibiotic therapy start IgA levels will measured in saliva of the patients and compared to baseline samples of the patients. 24 weeks
Primary Composition of the the gut microbiota following two weeks of intravenous antibiotic therapy The gut microbiota will be characterized by means of 16s rRNA sequencing. The gut microbiota composition following two weeks of intravenous (iv) antibiotic treatment will be compared to baseline samples of the patients. Two weeks
Primary Composition of the gut microbiota following four weeks of oral antibiotic therapy The gut microbiota will be characterized by means of 16s rRNA sequencing. The gut microbiota composition following four weeks of oral antibiotic treatment will be compared to baseline samples of the patients. Six weeks (including two weeks iv and four weeks of oral antibiotic therapy)
Primary Composition of the gut microbiota 24 weeks after antibiotic therapy start The gut microbiota will be characterized by means of 16s rRNA sequencing. The gut microbiota composition 24 weeks after antibiotic therapy start, including an at least 6-week antibiotic free period, will be compared to baseline samples of the patients. 24 weeks
Secondary Monitoring Rifampicin resistant S. aureus on the skin following two weeks of iv antibiotic therapy Skin and nose swabs will be plated on (rifampicin supplemented ) Mannitol-Salt-Agar plates and colonies will be compared to baseline samples of the patients. Two weeks
Secondary Monitoring Rifampicin resistant S. aureus on the skin following four weeks of oral antibiotic therapy Skin and nose swabs will be plated on (rifampicin supplemented ) Mannitol-Salt-Agar plates and colonies will be compared to baseline samples of the patients. Six weeks (including two weeks iv and four weeks of oral antibiotic therapy)
Secondary Monitoring Rifampicin resistant S. aureus on the skin 24 weeks after antibiotic therapy start Skin and nose swabs will be plated on (rifampicin supplemented ) Mannitol-Salt-Agar plates and colonies will be compared to baseline samples of the patients. 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05555459 - Performance and Safety Evaluation of Inion CompressOn Screw in Foot and Ankle Surgeries. PMCF Investigation N/A
Completed NCT03147222 - Function Focused Care: Fracture Care at Home N/A
Completed NCT03506958 - Patient Satisfaction in Treatment of Non-complex Fractures and Dislocations in Hospitals vs General Practitioners
Completed NCT04426981 - Behavioral Activation in Orthopaedic Trauma Patients: A Pilot Study N/A
Recruiting NCT04389749 - Continuous Passive Motion Following Fixation of Pelvic and Knee Fractures N/A
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Recruiting NCT05594199 - Feasibility of a Virtual Smoking Cessation Program N/A
Completed NCT04514601 - A Quality Improvement Project to Assess and Refine the Handover Process at Morning Trauma Meetings
Completed NCT05138640 - Bone Strength and Physical Activity in Patients With a Recent Clinical Fracture
Completed NCT02272972 - Performance Improvement Program on Imaging II
Completed NCT04215315 - Fracture In Preterm Infants Study (FIPIN Study)
Completed NCT03219125 - Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women
Completed NCT04151732 - Factors Associated With Future Fractures in Middle-aged Men and Women
Terminated NCT05655130 - Distal Radius Steroid Phase 1
Completed NCT02714257 - Working to Increase Stability Through Exercise N/A
Completed NCT02428244 - Let's STOP Now Trial: Smoking in Trauma Orthopaedic Patients N/A
Recruiting NCT04501510 - Ultrasonography in Fracture Management
Completed NCT03852095 - Single Time Management Diseases in Pediatric Traumatology
Completed NCT03370900 - Learning Retention in Radiograph Interpretation N/A
Completed NCT03819478 - Utilizing Protein During Weight Loss to Impact Physical Function and Bone N/A